Increased Fracture Risk in Women Treated with Aromatase Inhibitors versus Tamoxifen: Beneficial Effect of Bisphosphonates

In conclusion, fracture risk in postmenopausal women during aromatase inhibitor treatment, in real ‐life conditions, was>40% compared to tamoxifen, corroborating previous randomized controlled trials results. In high ‐risk patients, bisphosphonate users had lower significant fracture incidence during aromatase inhibitor therapy than non‐bisphosphonate‐users. Monitoring fracture risk and related risk factors in aromatase inhibitor patients is advisable.This article is protected by copyright. All rights reserved.
Source: Journal of Bone and Mineral Research - Category: Orthopaedics Authors: Tags: Original Article Source Type: research